A Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of SNS-595 Injection in Patients at least 60 Years of Age with Previously Untreated Acute Myeloid Leukemia
|Effective start/end date
|3/1/08 → 10/31/11
- Sunesis Pharmaceuticals, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.